Evaluating the Immune Response to COVID19 Vaccination in Immunodeficient Patients

Subjects with neurologic/immunologic condition: * at least 18 years of age * Known diagnosis of autoimmune neurologic disease (e.g. multiple sclerosis (MS), neuromyelitis optica, myelin oligodendrocyte glycoprotein (MOG) -associated disorder) or autoimmune blistering disease (AIBD). * EITHER: * Treated with an anti-CD20 (rituximab, ocrelizumab) medications for \>6 months at the time of vaccination (B-cell depletion therapy, BCDT) * On no immunomodulatory therapy for their autoimmune condition for \>6 months at the time of vaccination * Treated with a non-BCDT immunotherapy * No relapse of neurologic/immunologic disease for \>6 months prior to the time of enrollment * Subject is eligible and willing to receive COVID-19 vaccination in accordance with local and national guidelines, or subject intends to receive booster COVID-19 vaccination in accordance with recommendations from their primary medical team. * No active skin condition (e.g. open sores) preventing blood draw Healthy Controls: * at least 18 years of age * No evidence of neurological/immunologic disease/illness/condition * Subject is eligible and willing to receive COVID-19 vaccination in accordance with local and national guidelines, or subject intends to receive booster COVID-19 vaccination in accordance with recommendations from their primary medical team. * No active skin condition (e.g. open sores) preventing blood draw/skin biopsy Exclusion Criteria: * Use of high dose steroids for treatment of neur…